- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Journal of Obesity
Volume 2012 (2012), Article ID 319172, 7 pages
Choline Deficiency Attenuates Body Weight Gain and Improves Glucose Tolerance in ob/ob Mice
1Group on the Molecular and Cell Biology of Lipids and Department of Biochemistry, University of Alberta, Edmonton, AB, T6G 2S2, Canada
2Cardiovascular Research Group, University of Alberta, Edmonton, AB, T6G 2S2, Canada
3Department of Agricultural, Food and Nutritional Sciences, University of Alberta, Edmonton, AB, T6G 2S2, Canada
Received 1 November 2011; Revised 2 February 2012; Accepted 16 February 2012
Academic Editor: Bernhard Breier
Copyright © 2012 Gengshu Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. H. Zeisel, “Nutritional importance of choline for brain development,” Journal of the American College of Nutrition, vol. 23, no. 6, pp. 621S–626S, 2004.
- C. B. Hollenbeck, “The Importance of Being Choline,” Journal of the American Dietetic Association, vol. 110, no. 8, pp. 1162–1165, 2010.
- D. E. Vance and N. D. Ridgway, “The methylation of phosphatidylethanolamine,” Progress in Lipid Research, vol. 27, no. 1, pp. 61–79, 1988.
- C. J. Walkey, L. R. Donohue, R. Bronson, L. B. Agellon, and D. E. Vance, “Disruption of the murine gene encoding phosphatidylethanolamine N-methyltransferase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 24, pp. 12880–12885, 1997.
- R. L. Jacobs, Y. Zhao, D. P. Y. Koonen et al., “Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity,” Journal of Biological Chemistry, vol. 285, no. 29, pp. 22403–22413, 2010.
- I. Rubio-Aliaga, B. de Roos, M. Sailer et al., “Alterations in hepatic one-carbon metabolism and related pathways following a high-fat dietary intervention,” Physiological Genomics, vol. 43, no. 8, pp. 408–416, 2011.
- A. Maresca and C. T. Supuran, “Muscarinic acetylcholine receptors as therapeutic targets for obesity,” Expert Opinion on Therapeutic Targets, vol. 12, no. 9, pp. 1167–1175, 2008.
- M. B. Marrero, R. Lucas, C. Salet et al., “An α7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes,” Journal of Pharmacology and Experimental Therapeutics, vol. 332, no. 1, pp. 173–180, 2010.
- D. Gautam, O. Gavrilova, J. Jeon et al., “Beneficial metabolic effects of M3 muscarinic acetylcholine receptor deficiency,” Cell Metabolism, vol. 4, no. 5, pp. 363–375, 2006.
- Z. Li and D. E. Vance, “Phosphatidylcholine and choline homeostasis,” Journal of Lipid Research, vol. 49, no. 6, pp. 1187–1194, 2008.
- P. J. Raubenheimer, M. J. Nyirenda, and B. R. Walker, “A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet,” Diabetes, vol. 55, no. 7, pp. 2015–2020, 2006.
- H. M. Feldmann, V. Golozoubova, B. Cannon, and J. Nedergaard, “UCP1 ablation induces obesity and abolishes diet-induced thermogenesis in mice exempt from thermal stress by living at thermoneutrality,” Cell Metabolism, vol. 9, no. 2, pp. 203–209, 2009.
- E. Henkel, M. Menschikowski, C. Koehler, W. Leonhardt, and M. Hanefeld, “Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus,” Metabolism, vol. 54, no. 9, pp. 1168–1173, 2005.
- Y. O. Ilcol, M. Cansev, M. S. Yilmaz, E. Hamurtekin, and I. H. Ulus, “Peripheral administration of CDP-choline and its cholinergic metabolites increases serum insulin: muscarinic and nicotinic acetylcholine receptors are both involved in their actions,” Neuroscience Letters, vol. 431, no. 1, pp. 71–76, 2008.
- M. Cansev, Y. O. Ilcol, M. S. Yilmaz, E. Hamurtekin, and I. H. Ulus, “Choline, CDP-choline or phosphocholine increases plasma glucagon in rats: involvement of the peripheral autonomic nervous system,” European Journal of Pharmacology, vol. 589, no. 1-3, pp. 315–322, 2008.
- S. W. Djuric, N. Grihalde, and C. W. Lin, “Glucagon receptor antagonists for the treatment of type II diabetes: current prospects,” Current Opinion in Investigational Drugs, vol. 3, no. 11, pp. 1617–1623, 2002.
- W. Gu, D. J. Lloyd, N. Chinookswong et al., “Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 338, no. 1, pp. 70–81, 2011.
- D. Gao, S. Nong, X. Huang et al., “The effects of palmitate on hepatic insulin resistance are mediated by NADPH oxidase 3-derived reactive oxygen species through JNK and p38 MAPK pathways,” Journal of Biological Chemistry, vol. 285, no. 39, pp. 29965–29973, 2010.
- A. K. Ghoshal and E. Farber, “Choline deficiency, lipotrope deficiency and the development of liver disease including liver cancer: a new perspective,” Laboratory Investigation, vol. 68, no. 3, pp. 255–260, 1993.
- Y. K. J. Zhang, R. L. Yeager, Y. Tanaka, and C. D. Klaassen, “Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet,” Toxicology and Applied Pharmacology, vol. 245, no. 3, pp. 326–334, 2010.